Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18768644 | 1.00 | CTSS (0.42) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL14821901 | 0.98 | CTSS (0.43) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL18768476 | 0.95 | CTSS (0.43) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL14457549 | 0.95 | CTSS (0.43) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL18768477 | 0.95 | CTSS (0.43) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL7934082 | 0.95 | CTSS (0.43) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL13352032 | 0.94 | CTSS (0.42) | CTSSADRB3ADRA2BADRA2C | |
| SCHEMBL12224897 | 0.94 | CTSS (0.36) | CTSS | |
| SCHEMBL11930627 | 0.94 | CTSS (0.42) | CTSSADRB3ADRA2BADRA2C | |
| SCHEMBL19526362 | 0.93 | CTSS (0.42) | CTSSADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547645-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | JANSSEN PHARMACEUTICALS INC (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20180093943-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2018-04-05 | — | — | US | disclosed |
| EP-3239129-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170152253-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-06-01 | — | — | US | disclosed |
| US-9586893-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | Janssen Pharmaceuticals (US) | 2017-03-07 | — | — | US | disclosed |
| US-8927722-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-01-06 | — | — | US | disclosed |
| US-8722892-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | JANSSEN R&D IRELAND (IE) | 2014-05-13 | — | — | US | disclosed |
| US-8722892-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | JANSSEN R&D IRELAND (IE) | 2014-05-13 | — | — | US | disclosed |
| EP-2382198-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | JANSSEN PHARMACEUTICALS INC (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20130005976-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20120238746-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | JANSSEN SCIENCES IRELAND UC (IE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238746-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | JANSSEN SCIENCES IRELAND UC (IE) | 2012-09-20 | — | — | US | disclosed |
| US-8212043-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | JANSSEN R&D IRELAND (IE) | 2012-07-03 | — | — | US | disclosed |
| US-8212043-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | JANSSEN R&D IRELAND (IE) | 2012-07-03 | — | — | US | disclosed |
| US-20110257403-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | JANSSEN PHARMACEUTICA NV | 2011-10-20 | — | — | US | disclosed |
| WO-2010072742-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-07-01 | — | — | WO | disclosed |
| EP-2121674-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | TIBOTEC PHARM LTD (IE) | 2010-05-12 | — | — | EP | disclosed |
| US-20100041889-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | JANSSEN SCIENCES IRELAND UC (IE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041889-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | JANSSEN SCIENCES IRELAND UC (IE) | 2010-02-18 | — | — | US | disclosed |
| WO-2008092955-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041889-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | PREP, SPINT2, PEPD | CTSS 31/4885ADRB3 4662/4885ADRA2B 4698/4885 |
| US-20170152253-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | HAVCR2, RNASE1, CPB1 | CTSS 39/4885ADRB3 2178/4885ADRA2B 1691/4885 |
| US-20120238746-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | PREP, SPINT2, PEPD | CTSS 31/4885ADRB3 4662/4885ADRA2B 4698/4885 |
| US-20180093943-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | CTRC, HAVCR2, HGFAC | CTSS 51/4885ADRB3 4608/4885ADRA2B 4792/4885 |
| US-20130005976-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | HAVCR2, RNASE1, CPB1 | CTSS 39/4885ADRB3 2178/4885ADRA2B 1691/4885 |
| US-20110257403-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | CPN1, PREP, CTRC | CTSS 23/4885ADRB3 4598/4885ADRA2B 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.